Changes in select cytokines, KSHV viral load, clinical labs, and immunology profile in patients with symptomatic KSHV-MCD from baseline to end of therapy with R-Dox
| Laboratory . | Baseline-End R-Dox Median change (range) . | P* . |
|---|---|---|
| Cytokines | ||
| Log10hIL6, pg/mL | −0.46 (−1.49, +0.85) | .0026 |
| Log10IL10†, pg/mL | −1.68 (−3.08, +0.62) | .0002 |
| Log10KSHV, copies/106 PBMCs | −3.96 (−6.04, +0.92) | .0002 |
| Clinical labs used in response criteria | ||
| Hemoglobin, g/dL | +3.9 (−0.3, +10.1) | <.0001 |
| Platelets, ×1000/μL | +78 (−258, +261) | .19 |
| Albumin, g/dL | +0.8 (−1.2, +2.4) | .0008 |
| CRP, mg/dL | −3.0 (−14.7, +2.2) | .0013 |
| Immunologic markers | ||
| κ free light chains, mg/dL | −4.23 (−15.08, +1.69) | <.0001 |
| λ free light chains, mg/dL | −3.53 (−14.78, −0.66) | <.0001 |
| IgG, mg/dL | −390 (−2130, +1160) | .021 |
| IgA, mg/dL | +10, (−200, +174) | .89 |
| IgM, mg/dL | −40 (−98, +102) | .003 |
| IgE, IU/mL | −125 (−1516, +17) | <.0001 |
| CD4 cells/μL | +51 (−359, +345) | .07 |
| CD19 cells/μL | −191 (−81, −873) | <.0001 |
| Laboratory . | Baseline-End R-Dox Median change (range) . | P* . |
|---|---|---|
| Cytokines | ||
| Log10hIL6, pg/mL | −0.46 (−1.49, +0.85) | .0026 |
| Log10IL10†, pg/mL | −1.68 (−3.08, +0.62) | .0002 |
| Log10KSHV, copies/106 PBMCs | −3.96 (−6.04, +0.92) | .0002 |
| Clinical labs used in response criteria | ||
| Hemoglobin, g/dL | +3.9 (−0.3, +10.1) | <.0001 |
| Platelets, ×1000/μL | +78 (−258, +261) | .19 |
| Albumin, g/dL | +0.8 (−1.2, +2.4) | .0008 |
| CRP, mg/dL | −3.0 (−14.7, +2.2) | .0013 |
| Immunologic markers | ||
| κ free light chains, mg/dL | −4.23 (−15.08, +1.69) | <.0001 |
| λ free light chains, mg/dL | −3.53 (−14.78, −0.66) | <.0001 |
| IgG, mg/dL | −390 (−2130, +1160) | .021 |
| IgA, mg/dL | +10, (−200, +174) | .89 |
| IgM, mg/dL | −40 (−98, +102) | .003 |
| IgE, IU/mL | −125 (−1516, +17) | <.0001 |
| CD4 cells/μL | +51 (−359, +345) | .07 |
| CD19 cells/μL | −191 (−81, −873) | <.0001 |
This analysis includes 1 patient who progressed while on R-Dox and was subsequently diagnosed with primary effusion lymphoma.
The Wilcoxon signed-rank test was used to test the difference between the transformed or untransformed values at the identified time points. P < .005 indicates significance, whereas .005 < P < .05 indicates a strong trend.
Untransformed numbers capped at 2500 pg/mL, the upper limit for which the assay is validated.